Leerink Partnrs Has Negative Estimate for ALGN Q1 Earnings

Align Technology, Inc. (NASDAQ:ALGN) – Equities research analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of Align Technology in a research note issued on Wednesday, April 9th. Leerink Partnrs analyst M. Cherny now forecasts that the medical equipment provider will post earnings per share of $1.51 for the quarter, down from their prior forecast of $1.56. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Align Technology’s current full-year earnings is $7.98 per share. Leerink Partnrs also issued estimates for Align Technology’s FY2028 earnings at $11.35 EPS.

Several other equities research analysts have also recently commented on ALGN. Jefferies Financial Group dropped their target price on shares of Align Technology from $285.00 to $260.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Piper Sandler reaffirmed an “overweight” rating and set a $235.00 price objective (down from $270.00) on shares of Align Technology in a research report on Tuesday, March 18th. Bank of America upped their target price on Align Technology from $200.00 to $206.00 and gave the stock an “underperform” rating in a report on Friday, December 13th. Evercore ISI raised their target price on Align Technology from $240.00 to $260.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Align Technology in a research note on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $262.64.

Align Technology Stock Down 3.0 %

Shares of Align Technology stock opened at $160.14 on Friday. The company has a market cap of $11.72 billion, a PE ratio of 28.55, a P/E/G ratio of 2.24 and a beta of 1.73. The business has a 50 day moving average of $178.28 and a 200 day moving average of $207.89. Align Technology has a 52 week low of $141.74 and a 52 week high of $331.64.

Align Technology (NASDAQ:ALGN) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.96 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.43 by ($0.47). Align Technology had a net margin of 10.54% and a return on equity of 13.84%.

Hedge Funds Weigh In On Align Technology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALGN. Picton Mahoney Asset Management raised its stake in shares of Align Technology by 69.9% in the fourth quarter. Picton Mahoney Asset Management now owns 141 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 58 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new position in Align Technology in the 4th quarter worth about $31,000. Neo Ivy Capital Management bought a new position in Align Technology during the 3rd quarter valued at about $32,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Align Technology during the 4th quarter valued at about $35,000. Finally, Private Trust Co. NA grew its stake in shares of Align Technology by 113.4% in the fourth quarter. Private Trust Co. NA now owns 175 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 93 shares during the period. 88.43% of the stock is owned by institutional investors.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.